B
Bicycle Therapeutics plc (BCYC)
NMS – Real vaqt narxi. Valyuta: USD
4.72
+0.02 (0.43%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
4.72
+0.02 (0.43%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Bicycle Therapeutics plc, klinik bosqichdagi farmatsevtika kompaniyasi, Qo'shma Shtatlar va Buyuk Britaniyada mavjud davolash usullaridan kam ta'minlangan kasalliklar uchun dori vositalarining bir sinfini ishlab chiqadi. Kompaniyaning mahsulot quvurlari orasida zelenectide pevedotin, velosiped toksin konjugati (BTC) mavjud bo'lib, u yuqori nectin-4 ifoda etuvchi o'smalarni davolash uchun II bosqich klinik sinovlarida; nuzefatide pevedotin (EphA2), Ephrin A tipidagi retseptor 2 ifoda etuvchi o'smalarni davolash uchun I/II bosqich klinik sinovlarida bo'lgan BTC; BT7480, nectin-4 ni nishonga olgan va CD137 ni agonizatsiya qiluvchi velosiped o'smaga yo'naltirilgan immunitet xujayrasi agonisti molekulasi, I/II bosqichlarda; va MT1-MMP ni nishonga olgan terapevtik BRC molekulasi BT1702, buning uchun IND-ni kuchaytiruvchi tadbirlar davom etmoqda. Qo'shimcha ravishda, u preklinik sinovlarda CNS kasalligini nishonga olgan Novel CNS nishonlarini; preklinik sinovlarda nevromuskulyar kasallikni nishonga olgan Novel nevromuskulyar nishonlarini; va preklinik sinovlarda radiopharmatsivutikani nishonga olgan dasturlarni ishlab chiqadi. Shuningdek, kompaniya terapevtik sohalarda dasturlarni ishlab chiqish uchun biofarmatsevtika kompaniyalari va tashkilotlari bilan hamkorlik qiladi. U Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc va AstraZeneca AB bilan hamkorlik va litsenziya shartnomalariga ega. Bicycle Therapeutics plc 2009 yilda tashkil etilgan va Buyuk Britaniyaning Kembrij shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Christian Heinis | Scientific Founder |
| Dr. Jennifer Perry Pharm.D. | Chief Operating Officer |
| Dr. Kevin Lee M.B.A., Ph.D. | CEO & Executive Director |
| Dr. Michael Skynner B.sc. Ph.d., Ph.D. | Chief Scientific Officer |
| Dr. Phil Jeffrey | Senior VP of Pre-Clinical Development |
| Mr. Alistair Milnes | Chief Corporate Development Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-30 | 8-K | tm2613019d1_8k.htm |
| 2026-04-22 | DEF 14A | bcyc-20260617xdef14a.htm |
| 2026-04-22 | ARS | tm262946d3_ars.pdf |
| 2026-04-20 | 8-K | tm2612166d1_8k.htm |
| 2026-04-03 | PRE 14A | bcyc-20260617xpre14a.htm |
| 2026-03-17 | S-8 | tm268887d2_s8.htm |
| 2026-02-03 | 8-K | tm264844d1_8k.htm |
| 2026-01-12 | 8-K | tm262874d1_8k.htm |
| 2025-10-30 | S-8 | tm2529594d1_s8.htm |
| 2025-10-30 | 10-Q | bcyc-20250930x10q.htm |
| Mr. Travis Thompson | Chief Financial Officer |
| Mr. Zafar Qadir | Chief Legal Officer & General Counsel |
| Ms. Stephanie Yao | Senior Vice President of Investor Relations and Corporate Communications |
| Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE, Ph.D. | Co-Founder & Independent Non-Executive Director |